Related Experiment Video
Updated: Aug 16, 2026
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
Are serum levels of CD44 relevant in children with pediatric sarcomas?
Rejin Kebudi1, Inci Ayan, Vildan Yasasever
1Division of Pediatric Oncology, Istanbul University, Oncology Institute, Istanbul, Turkey. rejinkebudi@hotmail.com
Insights
Serum CD44 levels did not differ significantly between children with sarcomas and healthy children. This suggests serum CD44 is not a useful biomarker for diagnosing or predicting outcomes in pediatric sarcomas.
Area of Science:
- Biochemistry
- Immunology
- Pediatric Oncology
Background:
- CD44 is an adhesion receptor crucial for lymphocyte migration.
- Serum CD44 levels have been implicated in various malignancies.
- Pediatric sarcomas represent a group of rare childhood cancers.
Purpose of the Study:
- To investigate potential differences in serum CD44 levels between pediatric sarcoma patients and healthy controls.
- To evaluate the diagnostic and prognostic utility of serum CD44 in childhood sarcomas.
Main Methods:
- Serum samples were collected from 55 children diagnosed with sarcomas and 27 healthy children.
- Serum CD44 levels were quantified using enzyme-linked immunosorbent assay (ELISA).
- Statistical analysis compared CD44 levels between patient and control groups, considering stage and outcome.
Main Results:
- No statistically significant difference was found in serum CD44 levels between children with sarcomas and healthy children.
- Serum CD44 levels did not vary significantly across different patient groups or in relation to disease stage or outcome.
- The P-value for all comparisons exceeded 0.05, indicating no significant association.
Conclusions:
- Serum CD44 levels do not appear to be a valuable diagnostic marker for pediatric sarcomas.
- Serum CD44 levels are not a reliable prognostic indicator for children diagnosed with sarcomas.
- Further research may explore other biomarkers for improved diagnosis and prognosis in this patient population.
Background:
Variation in serum levels of CD44, which acts as an adhesion receptor involved in lymphocyte migration and binding, have been reported in some malignancies. The aim of this study is to compare serum levels of CD44 in children with sarcomas with those in healthy children.
Procedure:
CD44 levels were measured by enzyme-linked immunosorbent assay (ELISA) in serum samples taken at diagnosis from 55 children with sarcomas and from 27 healthy children of similar age, sex, and socioeconomic status.
Results:
There was no statistically significant difference between CD44 serum levels of children with sarcomas and those of healthy children. No significant difference was observed between CD44 serum levels of each patient group and those of control group (P > 0.05). There was no significant difference among CD44 serum levels of patient groups according to stage or outcome.
Conclusions:
In this study, serum CD44 levels were not found to be of value in the diagnosis or prognosis in children with sarcomas.
